Raynaud's Treatment Study (RTS)

Sponsor
National Heart, Lung, and Blood Institute (NHLBI) (NIH)
Overall Status
Completed
CT.gov ID
NCT00000530
Collaborator
(none)
69

Study Details

Study Description

Brief Summary

To determine the relative efficacy of usual medical care and a course of treatment by thermal biofeedback in reducing vasospastic attacks characteristic of Raynaud's syndrome. Also, to confirm the frequency and severity of attacks, examine the role of psychophysiological factors in precipitating attacks, and assess the influence of treatment on health quality of life.

Condition or Disease Intervention/Treatment Phase
  • Drug: nifedipine
  • Behavioral: biofeedback (psychology)
  • Procedure: electromyography
Phase 3

Detailed Description

BACKGROUND:

Primary Raynaud's phenomenon is a peripheral vascular disorder resulting in vasospastic attacks provoked by cold and/or emotional stress. Attacks most often occur in the fingers, but may occur in other extremities as well.

DESIGN NARRATIVE:

Randomized. Patients were assigned to one of four treatment groups: slow release Nifedipine, a calcium channel blocker; pill placebo; temperature biofeedback; or electromyograph biofeedback from the frontalis muscle. The primary endpoint was reduction in number of vasospastic attacks. Other endpoints included: other measures of Raynaud's attacks including frequency, severity, duration, response to laboratory-based cold challenge, and quality of life.

Study Design

Study Type:
Interventional
Allocation:
Randomized
Primary Purpose:
Treatment
Study Start Date :
Sep 1, 1992
Study Completion Date :
Jun 1, 1998

Outcome Measures

Primary Outcome Measures

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 75 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No

    Men and women with documented primary or secondary Raynaud's syndrome.

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • National Heart, Lung, and Blood Institute (NHLBI)

    Investigators

    • : Bruce Thompson, Clinical Trials & Surveys Corp (C-TASC)

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    , ,
    ClinicalTrials.gov Identifier:
    NCT00000530
    Other Study ID Numbers:
    • 73
    First Posted:
    Oct 28, 1999
    Last Update Posted:
    Apr 15, 2016
    Last Verified:
    Aug 1, 2004

    Study Results

    No Results Posted as of Apr 15, 2016